跨导管大动脉植入中的抗血栓治疗:关注性别差异
Mattia De Gregorio1, Andrea Denegri1, Filippo Luca Gurgoglione1
1Division of Cardiology, Parma University Hospital, 43126 Parma, Italy.
Journal of cardiovascular development and disease
|November 26, 2025
概括
通过导管大动脉植入术 (TAVI) 后最佳的抗血栓治疗需要平衡凝块预防和出血风险. 本综述强调了性别特异性的关键差异,特别是对于女性来说,以指导量身定制的治疗策略.
科学领域:
- 心脏病学 心脏病学
- 血管医学 血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 抗血栓治疗在输血管大动脉植入术 (TAVI) 后至关重要,以预防血栓栓塞事件.
- 平衡抗血栓益处与出血风险是复杂的和有争议的.
- 女性代表着一个日益增长的TAVI人群,具有独特的风险概况.
研究的目的:
- 审查目前关于TAVI后抗血栓策略的证据.
- 专注于血栓和出血风险的性别相关差异.
- 为女性TAVI患者提供量身定制的抗血栓治疗信息.
主要方法:
- 现有研究的综合文献综合.
- 对TAVI接受者的性别特异性结果的分析.
- 评估影响风险的解剖学,生理学和临床因素.
主要成果:
- 与男性相比,女性在TAVI后的血管并发症和出血率较高.
- 结果的差异与较小的血管大小,形性和血小板反应性有关.
- 目前的抗血栓策略可能无法充分解决性别特异性风险.
结论:
- 定制的抗血栓策略对于改善TAVI接受治疗的妇女的治疗结果至关重要.
- 为了有效的TAVI后管理,需要根据性别进行风险分层.
- 需要进一步的研究和专门的试验来完善这一群体的指导方针.
相关概念视频
Venous Thrombosis III: Interprofessional Care
268
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
268
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.0K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.0K
Atherosclerosis III: Management
301
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
301
Aortic Regurgitation III: Medical Management
379
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
379
Mitral Stenosis III: Medical Management
224
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
224
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K


